信贷投向是经济发展的"风向标"，资金流向折射产业变迁。今年前10个月，我国新增人民币贷款近15万亿元，这些"真金白银"投向了哪些领域？透过数据我 们发现，今年以来科技型中小企业贷款、绿色贷款增速均高于全部贷款增速，金融资源正加速流向科技创新、绿色发展、旅游消费等关键领域。 从不敢贷到放心投 破解科创企业融资困局 天津一家专注基因工程领域基础材料研发的企业，目前正全力攻关一项核心技术。 天津全和诚科技有限责任公司财务中心副总经理 孙岩：它的研发投入周期很长，资金投入量很大，需要我们有3年到4年的储备资金。 针对企业研发阶段的大额资金需求，人民银行天津市分行推出45项具体举措，推动金融服务精准对接技术研发、成果转化等关键环节需求。 邮储银行天津红桥支行行长 王世才：研发贷就是在科创贷基础上的一个升级迭代，然后给予客户更低的贷款利率、更长的贷款期限和更优的授信方案。根 据客户的研发实力、研发团队，还有产品的一些技术壁垒等因素进行定性定量的打分。 凭借过硬的研发实力，企业顺利通过评分，获得1300万元信贷资金。 天津全和诚科技有限责任公司财务中心副总经理 孙岩：拿到这笔研发贷之后，我们首先购买了实验仪器，同时扩大了我 ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Vor Biopharma Inc. ( VOR ) stock jumped to a high of $12 yesterday, gaining >20%, but as I discovered to my detriment recently, all is not exactly what it seems at the company. In this post I revisit aEdmund Ingham ...

Montreal, Quebec--(Newsfile Corp. - December 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary intracellular delivery platform that enables more potent, safer, and more effective antibody-based and radiotherapeutic treatments, is pleased to announce that the Shareholders approved all matters presented at the Company's annual general meeting of the shareholders held today, as follows:Setting the number of ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Jade Biosciences, Inc. (NASDAQ:JBIO) is one of the Best Micro-Cap Stocks to Invest in According to Analysts. Jade Biosciences (JBIO): Analyst Lauds Entry into Market On November 25, Clear Street analyst Kaveri Pohlman initiated coverage of Jade Biosciences, Inc. (NASDAQ:JBIO) stock with a Buy rating and $25 price target. In an investor note, the analyst underlined that there was conviction in JADE101, which was a potential best-in-class anti-APRIL mAb poised to reshape the IgAN therapeutic landscape. The ...

Voyager Therapeutics, Inc. (NASDAQ:VYGR) is one of the Best Micro-Cap Stocks to Invest in According to Analysts. Voyager Therapeutics (VYGR): Strong Q3 Prompts Bullish Coverage On November 12, HC Wainwright lowered the price target on Voyager Therapeutics, Inc. (NASDAQ:VYGR) to $25 from $30 and kept a Buy rating on the shares. Per the analyst, Voyager reported strong Q3 results, ending the quarter with $229M in cash and operational runway into 2028, while remaining eligible for up to $2.4B in partner mil ...

Immutep Limited (NASDAQ:IMMP) is one of the Best Micro-Cap Stocks to Invest in According to Analysts. Immutep Limited (IMMP): Firm Reports Positive Data from Trials In mid-November, Immutep Limited (NASDAQ:IMMP) reported positive data from two clinical trials of its drug candidate eftilagimod alpha, or efti. The firm revealed that a Phase 2 study of efti in combination with radiotherapy and Merck’s Keytruda showed significant efficacy in treating patients with soft tissue sarcoma in the neoadjuvant setti ...

Tectonic Therapeutic, Inc. (NASDAQ:TECX) is one of the Best Micro-Cap Stocks to Invest in According to Analysts. Tectonic Therapeutic (TECX): LifeSci Capital Reiterates Buy Rating Stocks chart On November 18, LifeSci Capital reiterated a Buy rating on Tectonic Therapeutic, Inc. (NASDAQ:TECX) stock with a price target of $88. Tectonic Therapeutic, Inc. (NASDAQ:TECX) is a biotechnology company that focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of ...

Dyne Therapeutics, Inc. ( DYN ) stock has had a pretty rocky 2025. Year to date, the stock is down about 21% and has relied mainly on hitting milestones as big positive catalysts. The way I now seeI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the rigor and chal ...

Dyne Therapeutics, Inc. ( DYN ) stock has had a pretty rocky 2025. Year to date, the stock is down about 21% and has relied mainly on hitting milestones as big positive catalysts. The way I now seeI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the rigor and chal ...